alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit








Exhibit 10.1 


CHEVRON CORPORATION
NON-EMPLOYEE DIRECTORS’ EQUITY COMPENSATION AND
DEFERRAL PLAN
[Year] Retainer Option Agreement


Name of Director:  [                ]
Please sign below and submit this Agreement.


Chevron Corporation has made the following grant to you, subject to the terms of the Chevron Corporation Non-Employee Directors’ Equity Compensation and Deferral Plan, as amended (the “Directors’ Plan”), and Rules Governing Awards under the Plan, as amended (the “Directors’ Plan Rules”). Both documents are incorporated into this Agreement and copies are available to you on the Chevron Diligent Boards portal or on request. By signing this Agreement and accepting this grant, you are agreeing to all the terms and conditions of the Directors’ Plan and the Directors’ Plan Rules.


		
	1.
	Date of Grant: [                ].




		
	2.
	The Exercise Price is $[            ] (1) per share, which is the Fair Market Value of the Shares subject to this Retainer Option on the Date of Grant.




		
	3.
	The number of Shares subject to this Retainer Option is [            ] Shares, subject to adjustment as provided in Section X of the Directors’ Plan.




		
	4.
	This Retainer Option is a nonstatutory stock option.




		
	5.
	This Retainer Option vests as follows: [          ] percent on [                   ], and the remaining [          ] percent on the earlier of the last day of the Annual Compensation Cycle to which the Grant relates or [                   ].




		
	6.
	This Retainer Option becomes exercisable on [                  ].




		
	7.
	This Retainer Option is transferable as provided in Section VI of the Directors’ Plan and Section VII of the Directors’ Plan Rules.




		
	8.
	This Retainer Option will expire ten years from the Date of Grant, or such earlier date as it expires or is forfeited pursuant to Section III of the Directors’ Plan Rules.




(1) The Exercise Price is the closing price of Chevron Corporation common stock on [                   ].






IN WITNESS WHEREOF, the Director has executed this Agreement on the day and year indicated below.








__________________
[Date]
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4929 Introduced in House (IH)]

110th CONGRESS
  1st Session
                                H. R. 4929

  To amend the Tariff Act of 1930 to clarify that the antidumping and 
   countervailing duty laws apply to the production of low-enriched 
                    uranium, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           December 19, 2007

  Mr. Whitfield of Kentucky introduced the following bill; which was 
              referred to the Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
  To amend the Tariff Act of 1930 to clarify that the antidumping and 
   countervailing duty laws apply to the production of low-enriched 
                    uranium, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. PRODUCTION OF LOW-ENRICHED URANIUM.

    (a) Antidumping Duty.--Section 731 of the Tariff Act of 1930 (19 
U.S.C. 1673) is amended in the last sentence--
            (1) by inserting ``(a)'' after ``includes''; and
            (2) by inserting before the period at the end the 
        following: ``, and (b) any contract or transaction for the 
        production of low-enriched uranium''.
    (b) Countervailing Duty.--Section 771 of that Act (19 U.S.C. 1677) 
is amended in paragraph (5) by adding at the end the following:
                    ``(G) Purchase of goods.--For purposes of 
                subparagraphs (D)(iv) and (E)(iv) of this paragraph 
                (5), the phrases `purchasing goods' and `goods are 
                purchased' include a contract or transaction involving 
                payment for the production of low-enriched uranium.''.
    (c) Application to Pending Proceedings.--The amendments made by 
this section apply in all pending or resumed antidumping and 
countervailing duty proceedings, including investigations, and in all 
appeals that have not become final and conclusive as of the date of 
enactment of this Act.
    (d) Application to NAFTA Countries.--Pursuant to Article 1902 of 
the North American Free Trade Agreement and section 408 of the North 
American Free Trade Agreement Implementation Act (19 U.S.C. 3438), the 
amendments made by this section shall apply with respect to goods from 
NAFTA countries.
                                 <all>
```
STATE v. STEELE

No. COA03-1481.

Court of Appeals of North Carolina.

Filed December 7, 2004.

Certification Date December 28, 2004.

Case reported without published opinion. No error.
<PAGE>


                                                                    Exhibit 31.2


                      CERTIFICATION PURSUANT TO SECTION 302
                        OF THE SARBANES-OXLEY ACT OF 2002


I, John E. Lushefski, Executive Vice President and Chief Financial Officer of
Millennium Chemicals Inc., certify that:

       1. I have reviewed this annual report on Form 10-K of Millennium
Chemicals Inc. as filed with the Securities and Exchange Commission on March 12,
2004 and as amended by Amendment No. 1 to the Annual Report on Form 10-K, filed
with the Securities and Exchange Commission on April 27, 2004, Amendment No. 2
to the Annual Report on Form 10-K, filed with the Securities and Exchange
Commission on August 9, 2004 and this Amendment No. 3 to the Annual Report on
Form 10-K, filed with the Securities and Exchange Commission on the date hereof;
and

     2. Based on my knowledge, this annual report, as amended, does not contain
any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period covered by
this annual report.


Date: September 23, 2004


                                              /s/ JOHN E. LUSHEFSKI
                                              ----------------------------------
                                              John E. Lushefski
                                              Executive Vice President and Chief
                                              Financial Officer
                                              (Principal Financial Officer)
I 

110TH CONGRESS 

1ST SESSION H. R. 511 

To pledge the faithful support of Congress to members of the United States 

Armed Forces serving in harm’s way. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 17, 2007 

Mr. SAM JOHNSON of Texas (for himself, Mr. BOEHNER, Mr. BLUNT, Mr. 

PUTNAM, Mr. CANTOR, Mr. MCCOTTER, Ms. GRANGER, Mr. CARTER, Mr. 

COLE of Oklahoma, Mr. DREIER, Mr. HOEKSTRA, Mr. HUNTER, Mr. 

KING of New York, Ms. ROS-LEHTINEN, Mr. BUYER, Mr. LEWIS of California, and Mr. YOUNG of Florida) introduced the following bill; which 

was referred to the Committee on Armed Services 

A BILL 

To pledge the faithful support of Congress to members of 

the United States Armed Forces serving in harm’s way. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. CONGRESSIONAL PLEDGE NOT TO CUT OFF OR 

4 RESTRICT FUNDING FOR UNITS AND MEM5 BERS OF THE ARMED FORCES IN HARM’S 

6 WAY. 

7 (a) FINDINGS.—Congress makes the following find8 ings: 


frosa on PROD1PC71 with BILLS
2 

•HR 511 IH

1 (1) On September 14, 2001, both the Senate 

2 and the House of Representatives passed S. J. Res. 

3 23 of the 107th Congress, which became Public Law 

4 107–40 and authorized the use of military force in 

5 Afghanistan. 

6 (2) On October 10, 2002, the House of Rep7 resentatives passed H. J. Res. 114 of the 107th 

8 Congress, which authorized the use of military force 

9 in Iraq. 

10 (3) After passage by the Senate, H. J. Res. 114 

11 became Public Law 107–243, the Authorization for 

12 Use of Military Force Against Iraq Resolution of 

13 2002. 

14 (4) Members of the United States Armed 

15 Forces have served honorably in their mission to 

16 fight terrorism and protect the greater security of 

17 the United States. 

18 (5) These members of the Armed Forces and 

19 their families have made many sacrifices, in many 

20 cases the ultimate sacrifice, to protect the security 

21 of the United States and the freedom Americans 

22 hold dear. 

23 (6) Congress and the American people are for24 ever grateful to the members of the Armed Forces 


frosa on PROD1PC71 with BILLS
3 

•HR 511 IH

1 for the service they have provided to the United 

2 States. 

3 (b) FAITHFUL SUPPORT OF CONGRESS.—Congress 

4 will not cut off or restrict funding for units and members 

5 of the Armed Forces that the Commander in Chief has 

6 deployed in harm’s way in support of Operation Iraqi 

7 Freedom and Operation Enduring Freedom. 

Æ 


frosa on PROD1PC71 with BILLS
EXHIBIT 31.2



SECTION 302 CERTIFICATION



I, Tom D. Benscoter, certify that:



1. I have reviewed this annual report on Form 10-KSB/A of Prosoft Learning Corporation;



2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;



3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;



4. The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;



(b) Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and



(c) Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most
recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting.



5. The registrants other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent function):



(a) All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and



(b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrants internal control over financial reporting.



|Date: | November 28, 2005
|----- | -----------------

|                                        
|----------------------------------------
|                                        
|                                        
|/s/ TOM D. BENSCOTER                    
|Tom D. Benscoter Chief Financial Officer
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                         270,262
<SECURITIES>                                22,127,276
<RECEIVABLES>                                  579,603
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                38,964
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              23,016,105
<CURRENT-LIABILITIES>                          535,500
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  22,480,605
<TOTAL-LIABILITY-AND-EQUITY>                23,016,105
<SALES>                                              0
<TOTAL-REVENUES>                             1,204,597
<CGS>                                                0
<TOTAL-COSTS>                                  154,268
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              1,050,329
<INCOME-TAX>                                 1,050,329
<INCOME-CONTINUING>                          1,050,329
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,050,329
<EPS-PRIMARY>                                      .85
<EPS-DILUTED>                                        0
        

</TABLE>
**EXHIBIT32.2**

**CERTIFICATIONSPURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

     In connectionwith the Quarterly Report of National Beef Packing Company, LLC (the Company)on Form 10-Q for the period ended November 25, 2006 as filed with theSecurities and Exchange Commission on the date hereof (the Report), I, Jay D.Nielsen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, that: 

     (1)The Report fully complies with the requirements of section 13(a) or 15(d) of theSecurities Exchange Act of 1934, as amended; and 

     (2)The information contained in the Report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.

|     |  |                                         |
|-----|--|-----------------------------------------|
| By: |  | /s/ Jay D. Nielsen                      |
|     |  | Jay D. Nielsen*Chief Financial Officer* |

Date: January 5, 2007
Steven Tyron McGREGOR v. STATE of North Carolina.

No. 427A04.

Supreme Court of North Carolina.

December 2, 2004.

Steven Tyron McGregor, Pro Se.

William P. Hart, Special Deputy Attorney Genera, Kristy M. Newton, District Attorney, for State of NC.

***ORDER***

Upon consideration of the notice of appeal from the North Carolina Court of Appeals, filed by Plaintiff on the 13th day of August 2004 in this matter pursuant to G.S. 7A-30, the following order was entered and is hereby certified to the North Carolina Court of Appeals: the notice of appeal is

> "Dismissed ex mero motu by order of the Court in conference, this the 2nd day of December 2004."
James E. LANG, Petitioner v. FLORIDA

No. 19-6453

Supreme Court of the United States.

January 13, 2020

Petition for writ of certiorari to the District Court of Appeal of Florida, Second District denied.
[Federal Register Volume 87, Number 124 (Wednesday, June 29, 2022)]
[Notices]
[Page 38766]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-13801]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; Development of Radiation/Nuclear 
Medical Countermeasures (MCMs) and Biodosimetry Devices.
    Date: July 28-29, 2022.
    Time: 10:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G42, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Sandip Bhattacharyya, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G42, 
Rockville, MD 20852, (240) 292-0189, <a href="/cdn-cgi/l/email-protection#a1d2c0cfc5c8d18fc3c9c0d5d5c0c2c9c0d3d8d8c0e1cfc8c98fc6ced7"><span class="__cf_email__" data-cfemail="2457454a404d540a464c45505045474c45565d5d45644a4d4c0a434b52">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: June 23, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-13801 Filed 6-28-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
DUNGAN & MITCHELL, P.A. v. DILLINGHAM CONST. CO., INC.

No. COA03-1411-2

Court of Appeals of North Carolina

Filed February 15, 2005

Certification Date March 7, 2005

Case reported without published opinion. No error.
I 

110TH CONGRESS 

2D SESSION H. R. 5074 

To extend the suspension of duty on Desmodur RF-E. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 18, 2008 

Mr. TIM MURPHY of Pennsylvania introduced the following bill; which was 

referred to the Committee on Ways and Means 

A BILL 

To extend the suspension of duty on Desmodur RF-E. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. DESMODUR RF-E. 

4 (a) IN GENERAL.—Heading 9902.12.17 of the Har5 monized Tariff Schedule of the United States (relating to 

6 mixtures of tris(4-isocyanatophenyl)thiophosphate and 

7 ethyl acetate and monochlorobenzene as solvents) is 

8 amended by striking ‘‘12/31/2009’’ and inserting ‘‘12/31/ 

9 2011’’. 

10 (b) EFFECTIVE DATE.—The amendment made by 

11 subsection (a) applies to goods entered, or withdrawn from 


smartinez on PRODPC61 with BILLS
2 

•HR 5074 IH

1 warehouse for consumption, on or after the 15th day after 

2 the date of the enactment of this Act. 

Æ 


smartinez on PRODPC61 with BILLS
# Official Journal C 214/1 Se

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 214 |
| | |
| English edition | Information and Notices | Volume 481 September 2005 |

ISSN 1725-2423

Official Journal

of the European Union

C 214

English edition

Information and Notices

Volume 481 September 2005

---

| Notice No | Contents | page |
| --- | --- | --- |
| | I   Information |
| | Commission |
| 2005/C 214/1 | Euro exchange rates | 1 |
| 2005/C 214/2 | Authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty — Cases where the Commission raises no objections | 2 |

Notice No

Contents

page

I   Information

Commission

2005/C 214/1

Euro exchange rates

1

2005/C 214/2

Authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty — Cases where the Commission raises no objections

2

---

| | |
| --- | --- |
| 2005/C 214/3 | Notice to readers — COM Documents | s3 |

2005/C 214/3

Notice to readers — COM Documents

Notice to readers — COM Documents

s3

---

| EN | |
| --- | --- |

EN
[DO NOT PUBLISH]

IN THE UNITED STATES COURT OF APPEALS FOR THE ELEVENTH CIRCUIT

________________________ No. 14

- 10895 Non

- Argument Calendar

________________________ D.C. Docket No. 3:12

- cr - 00142

- MMH

- PDB

- 1
UNITED STATES OF AMERICA, Plaintiff

- Appellee,
versus ROGER G JOLLEY, Defendant

- Appellant.

________________________ Appeal from the United States District Court for the Middle District of Florida

________________________ (October 21, 2014) Before MARCUS , WILLIAM PRYOR and MARTIN , Circuit Judges. PE R CURIAM: Craig L. Crawford, appointed counsel for Roger Jolley in this direct criminal appeal, has moved to withdraw from further representation of the appellant and

Case: 14-10895 Date Filed: 10/21/2014 Page: 1 of 22 filed a brief pursuant to Anders v. California , 386 U.S. 738, 87 S.Ct. 1396, 18 L.Ed.2d 493 (1967). Our independent review of the entire record reveals that counsel’s assessment of the relative merit of the appeal is correct. Because independent examination of the entire record reveals no arguable issues of merit, counsel’s motion to withdr aw is GRANTED , and Jolley’s convictions and sentences are AFFIRMED
.

Case: 14-10895 Date Filed: 10/21/2014 Page: 2 of 2
Andre DENNIS, Petitioner, v. Steven JOHNSON, Administrator, New Jersey State Prison, et al.

No. 19-7734.

Supreme Court of the United States.

April 6, 2020

Petition for writ of certiorari to the United States Court of Appeals for the Third Circuit denied.